ALKBH5 and urinary bladder cancer: Mechanistically, ALKBH5 impeded the progression of bladder cancer and enhanced the sensitivity of bladder cancer cells to cisplatin by modulating the glycolysis pathway through CK2α in an m6A-dependent manner [66].